AZ's MedImmune launches PhIII study of benralizumab; Veracyte raises $65M in IPO; Incyte touts results for JAK1 inhibitor for RA;

@FierceBiotech: Still trending: The ax drops at troubled Merck as big restructuring gets underway. Article | Follow @FierceBiotech

@JohnCFierce: We'll have some hiring news soon. but in the meantime still looking for a savvy devices writer. Also, have my eye out for a U.K. writer. | Follow @JohnCFierce

@DamianFierce: Ex-Calistoga chief Gallagher joins VC Frazier Healthcare to steer biotech bets. ICYMI yesterday | Follow @DamianFierce

@EmilyMFierce: Check out my report on 5 promising preclinical drug programs. Special report | Follow @EmilyMFierce

> AstraZeneca's ($AZN) biologics subsidiary MedImmune has launched a Phase III study of the asthma drug benralizumab, one of its top prospects in the clinic. The move marks another expansion of AstraZeneca's late-stage pipeline as it tries to counter concerns about its weak R&D record in recent years. Story

> The South San Francisco-based diagnostics company Veracyte ($VCYT)--a FierceMedicalDevices Fierce 15 company--raised $65 million in its IPO, selling 5 million shares at $13, the low end of the range. Morgan Stanley and Leerink Swann are acting as joint book-running managers for the offering. William Blair and Cowen and Company are acting as co-managers. Story

> Incyte ($INCY) is touting the results of a 60-patient study of its JAK1 inhibitor for rheumatoid arthritis. Story

Medical Device News

@FierceMedDev: New feature: Q3's top 5 diagnostics VC deals. Special report | Follow @FierceMedDev

> Kona notches solid results for novel renal denervation tech. Article

> CVRx brings in $12M more for hypertension device trial work. More

> Medtronic eyes faster FDA nod as CoreValve aces pivotal study. News

> Theragenics completes $68M sale to private equity outfit Juniper. Item

Pharma News

@FiercePharma: Tuesday's top news: Vertex to slash 370 jobs in shift away from hep C drug Incivek. Report | Follow @FiercePharma

@EricPFierce: Wockhardt profits crater as bans by FDA MHRA start to take a toll. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: Wondering which companies will be hardest-hit by patent losses in 2014? Special report | Follow @CarlyHFierce

> Teva CEO Jeremy Levin steps down amid board squabble. More

> GSK closing plant ASAP, gives workers pay instead of notice. Article

Biomarkers News

> Hopkins team spotlights biomarkers ratio that tags presymptomatic Alzheimer's. More

> Researchers inch closer to breath test for lung cancer. Report

> Biomarker flags patient response to certain melanoma treatments. Story

> GE wins FDA approval for a second Alzheimer's imaging agent. Item

> Inova picks up rheumatoid arthritis biomarkers from Dutch university. Article

Drug Delivery News

@MichaelGFierce:  promises new frontier as  decides how to regulate. Editor's corner | Follow @MichaelGFierce

> Mesoporous delivery technique allows key compounds to aid stem cell transplant. Article

> Pulmatrix heralds early stage results for COPD dry powder tech. More

> Alnylam pushes for PhI trial of orphan hemophilia RNAi drug. Story

> Dual-surface Janus nanoparticle offers cancer diagnosis, drug delivery. Article

> Layered nanoparticles deliver RNA, chemo for one-two punch. Item

Diagnostics News

@MarkHFierce: DARPA is hard at work at a brain monitoring implant to help combat depression and other conditions. FierceMedicalDevices item | Follow @MarkHFierce

> Quest sued by Myriad in flap over BRCA test patents. Item

> Swedish team tracks down soft tissue pain with PET scanner. Story

> GE Healthcare eyes 2014 for U.S. launch of Alzheimer's imaging agent. More

> NextCODE CEO predicts rapid Dx growth with licensed deCODE sequencing tech. Story

> Johns Hopkins blood test points possible way toward early pancreatic cancer detection. Article

Suggested Articles

Biogen stunned the biotech world Tuesday when it said it would file aducanumab for approval. Now that the dust has settled, what are analysts saying?

Biocytogen uses chromosome engineering for the in situ replacement of mouse antibody genes with the human counterparts.

Eli Lilly is canning the lead program for the crown jewel of its $1.6 billion Armo buyout after the drug put up a poor showing in pancreatic cancer.